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Abstract  
 
Objective: Literature regarding acute human toxicity of mycophenolate mofetil (MMF) and 
enteric-coated mycophenolate sodium (EC-MPS) is limited. Our objectives were to describe 
all cases of overdose with MMF or EC-MPS reported to the Swiss Toxicological Information 
Centre (STIC) or in the literature between 1995-2013.  
Research design and methods: Observational case-series and systematic literature search to 
determine circumstances, magnitude, management and outcome of overdose with MMF or 
EC-MPS.  
Results: Of 152,762 reports to STIC, 15 (7 paediatric) involved overdose with MMF (n=13) or 
EC-MPS (n=2). Three cases from other centres were identified from a systematic literature 
search. The magnitude of overdose ranged from 1.2 to 16.7 (median 2.9) times usual dose. 
Six (33%) MMF overdoses had attributable symptoms which included abdominal pain, 
vomiting, headache and dizziness. The majority of findings were minor, although a 9-fold 
MMF overdose caused hypotension 8 h after ingestion and a 12.5-fold overdose caused 
leukopenia after 5 days. Symptoms did not occurr in patients who took 2.5-times or less of 
their usual MMF dose. Gastrointestinal decontamination measures with activated charcoal 
were undertaken in one third of cases.  
Conclusions: Acute MMF and EC-MPS overdoses had a favourable outcome in all cases 
reported to STIC and in the literature. 
 
Key words: Human toxicity, mycophenolate mofetil, mycophenolic acid, enteric-coated 
mycophenolate sodium, overdose. 
 
  
1. Introduction 
 
Mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS) are 
selective immunosuppressants used in combination with other immunosuppressive agents 
for the prevention of acute rejection after solid organ transplantation in adults and children 1, 
2. They are also used in the treatment of several autoimmune diseases 3. Compared to the 
frequently prescribed thiopurines, these are newer active substances which have been 
approved for use in Switzerland since 1995 (MMF) and 2002 (EC-MPS). MMF is the prodrug 
and EC-MPS the sodium salt of the active substance mycophenolic acid (MPA). The term 
MPA will be used when discussing toxicity because it is the active form of both drugs.  
MPA is a selective, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH) 4. 
IMPDH is the rate-limiting enzyme in the synthesis of guanosine nucleotides. As T- and B- 
lymphocyte-proliferation is entirely dependent on the de novo synthesis of guanosine (unlike 
other cell types which can utilise guanosine from a salvage pathway), MPA exerts a much 
more potent cytostatic effect on lymphocytes than on other cell types 4.  The most frequently 
reported side effects of MPA are gastrointestinal disturbances, which are dose-dependent 
and include nausea, diarrhoea, anorexia, abdominal cramps and vomiting. Reversible, dose-
related haematological effects such as anaemia, leukopenia neutropenia and 
thrombocytopenia are also observed 5. The long term therapeutic use of MMF and EC-MPS 
appears to be safe and not to show any serious consequences 6, 7.  
MMF is rapidly absorbed and de-esterified to MPA after oral administration; the absolute 
bioavailability of MPA is 94%. Intravenous administration of MMF leads to a comparable 
exposure as observed after oral administration of the same dose 1. EC-MPS is readily 
absorbed in the small intestine because its enteric coating dissolves at pH 5.5. The ingestion 
of equimolar doses of MMF and EC-MPS lead to similar peak concentrations and exposure, 
and the degree of IMPDH inhibition is also comparable. The intra- and interpatient 
pharmacokinetic variability is high for both MPA formulations 8, 9.  
The majority of MPA is metabolized in the liver by UDP-glycuronosyltransferases [UGT] in a 
phase II glucuronidation process. MPA is converted to a major 7-O-glucuronide metabolite 
(MPAG) which is pharmacologically inactive 10. MPAG is excreted into bile and therefore 
back into the bowel where gut bacteria can deglucuronidate it to reform MPA which is 
reabsorbed. This enterohepatic recirculation results in a `second peak` approximately 6 – 8 
hours after ingestion, which could add to or prolong toxicity. In addition to MPAG, two other 
metabolites, MPA-acyl-glucoronide (AcMPAG) and MPA-phenyl-glucoside (glucoside-MPA), 
are observed in plasma 11. In vitro analysis has shown that AcMPAG is pharmacologically 
active and is likely responsible for the gastrointestinal toxicity of MPA 12. Approximately 93% 
of the glucuronide metabolites are renally excreted 10.  
Patients taking MMF or EC-MPS may be intentionally or accidentally exposed to acute 
overdose. In addition, their household contacts may have access to these drugs and also be 
at risk of overdose. The purpose of this study was to investigate the circumstances, 
management and outcomes of overdoses with MMF or EC-MPS using data reported to a 
single national poison centre and data reported in the literature during an 18-year period.  
2. Methods 
 
2.1 Study design 
 
Specific ethics approval was not required for this observational study due to the nature of the 
study design in accordance with the regulations of the cantonal ethics committee Zurich, 
Switzerland which also stated that anonymised data generated during patient care can be 
used retrospectively for research purposes without obtaining written consent. We performed 
a retrospective review of all acute overdoses involving MMF or EC-MPS in adults and 
children (<16 years) either alone or in combination with other drugs that had been reported to 
the Swiss Toxicological Information Centre (STIC) between April 1995 and August 2013 (for 
further details, see the online supplement). Cases were assigned an internal identification 
number so neither the patients or caregivers nor the reporting professionals could be 
identified by the investigators. 
A systematic literature-search was performed in MEDLINE and EMBASE from 1995 to 2013 
using the terms `mycophenolate` (which encompases mycophenolate sodium, mycophenolic 
acid and mycophenolate mofetil) and `overdose`. Furthermore the relevant product 
information 1, 2 and guidance on the management of acute overdose 13, 14 were examined.  
 
2.2 Circumstances and symptoms of overdose 
 
The circumstances of overdose were categorised into `suicidal` for cases of intentional 
overdose, `domestic` for cases of accidental overdose in the home and `iatrogenic` for those 
due to a prescribing or administration error by a healthcare professional. The severity of 
symptoms were graded in accordance with the Poisoning Severity Score (PSS) as ‘minor’, 
for mild, transient and spontaneously resolving symptoms/signs; ‘moderate’, if at least one 
pronounced or prolonged symptom/sign was recorded; ‘severe’, if at least one severe or life-
threatening symptom/sign was observed, or `fatal`, if the overdose was the recorded cause 
of death 14. Cases were assessed for association between symptoms and the MMF or EC-
MPS overdose by an expert panel including a senior clinical toxicologist and a clinical 
pharmacologist, both with additional qualifications in general internal medicine, using the 
World Health Organisation Uppsala Monitoring Centre (WHO-UMC) standardised case 
causality assessment criteria originally developed for the assessment of adverse drug 
reactions 16. The magnitude of overdose, co-ingestion of other medication (in patients with 
multiple drug overdose or taking other drugs in the therapeutic dose range) and co-
morbidities were taken into consideration. Associations were classified as `certain`, `likely`, 
`possible` and `unlikely` (Table S1 online supplement). 
 
2.3 Data analysis 
 
Descriptive statistics were used to analyse grouped data. Overdoses in mg/kg for adults and 
in mg/m2 in children were compared with usual therapeutic doses by determining the multiple 
of the subject`s usual therapeutic dose (dose ingested or dose received/usual dose) as 
performed in our previous studies 17, 18. In subjects who did not normally receive MMF or EC-
MPS or in cases where the usual maintenance dose was not known, the magnitude of 
overdose above the maximum licensed dose was determined. In Switzerland the maximum 
licensed oral MMF dose for treatment of adults is 2 - 3 g/day, depending on indication. The 
recommended dose for oral MMF in children and adolescents is 600 mg/m2 body surface 
area twice daily up to a maximal daily dose of 2 g. The maximum licensed dose for 
intravenous MMF is 1 g/12 h 1. The infusion should be administered slowly over a period of 2 
hours. The recommended dose of EC-MPS for adults is 720 mg twice daily 2. EC-MPS is not 
licensed for children in Switzerland 2, but is licensed in other countries such as the United 
States of America 19. The Food and Drug Administration licensed dose is 400 mg/m2 twice 
daily for renal transplant rejection prophylaxis in children aged 5 – 16 years 19. Missing data 
regarding patient weight was computed as detailed in the online supplement.  
The drug half-life was calculated according to the standard pharmacokinetic equation given 
in the online supplement in cases where serial drug concentration measurements had been 
performed 
3. Results 
 
3.1 Cases 
A total of 152,762 reports by healthcare professionals to the STIC of confirmed or suspected 
overdose with any substance occurred during the study period. Of these, 13 were with MMF 
and two with EC-MPS (7 paediatric cases). In 14 cases the route of administration was oral 
(tablets, capsules or oral solution) while in one case MMF was administrated as an 
intravenous solution. The majority of the cases were reported by hospital doctors (n=13), one 
case by another doctor and one case by a caregiver. Demographic characteristics, 
circumstances of overdose, the magnitude of overdose and the availability of follow-up data 
are given in Table 1 along with the details of three cases published in the literature 20-22. 
Adults and children are presented separately. Table 2 shows the details of each individual 
case. For the cases reported to STIC, the mean age of adult cases was 31.5 years (range 
19– 50). Six (40%) cases involved patients already receiving immunosuppression, eight 
cases (53%) did not normally receive immunosuppression and in one case the underlying 
diagnosis was not known. Six (86%) of the seven accidental domestic overdoses were in 
children (age range 1.5-9 years). Four of these were living with parents or siblings 
undergoing treatment with MMF or EC-MPS. One case of dosing error in the home (patient 
13) involved a mother administering 2 ml of dry MMF powder to her child rather than 
reconstituting the powder with water and administering 2 ml of the resulting solution as per 
instructions. The cases labelled `15`, `16` and `17` in tables 2 and 3 are those which have 
been published previously20-22. All three were females with an underlying diagnosis requiring 
immunosuppression. In two cases (patients 15 and 16) the overdose was deliberate (with 
suicidal intent) while in patient 17 the overdose was caused iatrogenically during a drug 
switch from twice daily MMF to once daily EC-MPS in an attempt to improve adherence 
(although EC-MPS is licensed to be given every 12 hours 2). Therapeutic drug monitoring 
showed a significantly higher drug exposure after once daily 1.44 g enteric-coated EC-MPS 
than under the previous MMF 1 g twice-daily dose 22. The dose of EC-MPS was 
subsequently reduced to 900 mg once daily.  
 
3.2 Magnitude of overdose 
Table 3 shows the magnitude of overdose in relation to the patient`s usual maintenance dose 
or - for treatment-naïve individuals - in relation to the maximum licensed dose. Two of the 
exposures were retrospectively found to be equal to or less than the maximum licensed dose 
and were a case of accidental ingestion by a child (patient 2) and a case of iatrogenic error 
(patient 18). These two cases were considered `accidental exposures within the therapeutic 
range` rather than `overdose` and were not included in the analysis of symptom development 
in order to accurately reflect the effect of true overdose. The overdoses ranged from 1.2 to 
16.7 times the usual or maximum licensed dose (Table 2).  
Drug concentration measurements were only available in one case reported to STIC. Patient 
7 (a 12-year-old female) had a plasma MPA concentration of 0.5 mg/l approximately 24 
hours after overdose with 5 g MMF. Being a drug which is administered twice daily, no data 
regarding expected plasma concentrations 24 hours after a single administration in children 
exist, so interpretation of this result was not possible. However, by way of comparison, the 
therapeutic range of trough MPA concentrations after liver transplantation is 1 – 3.5 mg/L 
and 2.5 – 4.5 mg/l after heart transplantation 23.  
Plasma drug concentration measurements were available for all the published cases. The 
measured serial MPA concentrations after ingestion of 10 g MMF (patient 15) were 44.1 mg/l 
(5 hours after ingestion), 5.6 mg/l (10 hours after ingestion) and 0.3 mg/l (21 hours after 
ingestion) 21. Serial plasma MPA concentrations after ingestion of 25 g (patient 16) were 37.2 
mg/l (20 hours after ingestion), 1.1 mg/l (24 hours after ingestion), 0.4 mg/l (48 hours after 
ingestion) and 0.1 mg/l (72 hours after ingestion) 20. Patient 17 had a maximum MPA 
concentration of 45.1 mg/l three hours after ingestion of 1440 mg EC-MPS 22.  
 
3.3 Pharmacokinetic calculations 
The half-lives of MPA were 2.6 h and 6.1 h in patients 15 and 16, respectively. By reading 
raw data points off the concentration-time graph in the publication describing patient 17 22, an 
estimated half-life of 7.4 h after ingestion of EC-MPS could be calculated. 
 
3.4 Outcomes  
The outcomes of overdose are given in detail in Table 3. In the cases reported to STIC, MMF 
overdoses were judged to have caused or contributed to symptoms or abnormal clinical 
findings in 4 of the 13 true overdose cases.  All symptoms attributable to mycophenolate 
were minor and included abdominal pain (n=2), vomiting (n=2), headache (n=2) and 
dizziness (n=1).  One patient (patient 3) experienced a fall in blood pressure from 113/68 
mmHg on admission 4 hours after overdose to 90/40 mmHg 8 hours after overdose. The 
hypotensive episode lasted 2 hours and responded to intravenous fluid therapy. It was 
classified as a moderate sign. No changes in blood count were observed in the cases 
reported to STIC; one case reported in the literature (patient 16) developed moderate 
leukopenia with a nadir of 2040/mm3 5 days after overdose (patient`s usual range 3500 to 
5000/mm3, normal range 5000 – 10000/mm3). None of the EC-MPS overdoses reported to 
STIC or in the literature caused symptoms, however these overdoses were all modest in size 
(1.2 – 2 times usual or maximum licensed dose). Overall, patients who developed symptoms 
after overdose had been exposed to a mean of 8.5 +/-4.7 times their usual or maximum 
licensed dose compared to asymptomatic patients who were exposed to 2.4 +/-1.7 times 
their usual or maximum licensed dose. No patient taking 2.5 times or less than their usual or 
maximum licensed dose developed symptoms.  
 
3.5 Management  
Of the cases reported to STIC, three patients were discharged home on the same day of 
presentation either immediately after initial evaluation in the emergency room or after a brief 
period of observation. All three were asymptomatic. Five patients were admitted to acute 
medical wards (one subsequently self-discharged against medical advice). Of those 
hospitalised, median length of hospital stay was 1 day (range 1-2). Hospitalisation status was 
unknown in 4 patients. Care was transferred from acute medical to psychiatric in-patient 
services in one case.  
The recommendation for use and subsequent use of decontamination measures is shown in 
Table 3. Of the cases reported to STIC, decontamination measures with activated charcoal 
were performed in four cases; all of which were children who presented to emergency 
services within one hour of ingestion. In three patients it is not known if any action was 
performed. However, the administration of activated charcoal was recommended in two of 
these cases. Decontamination with activated charcoal was also performed in the paediatric 
patient who experienced accidental exposure within the therapeutic range (patient 2). For the 
patients who did not receive activated charcoal, median time until presentation to emergency 
services was two hours (range <1 – 5.5 h). A follow-up blood count was performed in 1 case 
of MMF overdose (patient 7, one day after overdose) with a normal result.  
Among the cases reported in the literature, patient 15 presented to the emergency room 4 
hours after ingestion and was treated with activated charcoal and supportive care 
(promethazine for nausea and intravenous fluids). She was hospitalized, but the length of 
stay was not specified 21. Patient 16 presented to the emergency room approximately 10 
hours after ingestion, where she was treated with activated charcoal and oral cholestyramine 
(8 g) every 8 hours. She was hospitalized for 6 days 20. Patient 17 underwent a dose-
reduction of her maintenance EC-MPS.  
 
3.6 Effect of decontamination  
All four patients who received activated charcoal after overdose remained asymptomatic 
compared to four of the eight (50%) who did not undergo gastrointestinal decontamination 
among the cases reported to STIC. The mean multiple above patients’ usual or maximum 
licensed dose of MMF or EC-MPS was higher in untreated patients (4.1 ± 2.9) than in treated 
patients (1.2 ± 0.3). No adverse effects resulting from treatment with activated charcoal were 
reported. Patient 16 who was treated with oral cholestyramine in addition to activated 
charcoal developed mild anorexia, headache and moderate leukopenia, despite the high 
ingested dose 20. 
4. Discussion 
 
This case-series analysis of MMF and EC-MPS overdoses reported to a single national 
poison centre between 1995 and 2013 adds a further 15 cases to the three case reports 
currently published in the medical literature. Acute overdoses of these substances are rare 
and seem to be generally well tolerated. As the experience with acute overdose of MMF and 
EC-MPS in humans is very limited, the data presented here gives an insight into the patterns, 
management strategies and outcomes of MMF and EC-MPS overdoses. 
 4.1 Circumstances of overdose 
A number of important issues emerge when examining the circumstances of overdose with 
MMF or EC-MPS. In contrast to our previous findings for calcineurin inhibitor (CNI) overdose 
where iatrogenic errors accounted for 46% of the reported cases 17, iatrogenic dosing errors 
only accounted for 2 (11%) of all the cases presented here. This may be due to the fact that 
liquid formulations (intravenous or oral), which accounted for almost three quarters of the 
CNI iatrogenic overdoses, are much less commonly used for the administration of MMF, and 
EC-MPS is only available in tablet form. Nonetheless, extra vigilance should be paid when 
dealing with such drug forms, as mistakes can easily be made when procedures are 
unfamiliar. This also holds true for people who take responsibility for drug administration in 
the home, in particular parents, who should be clearly instructed how to reconstitute powder 
to make an oral solution. The majority (75%) of MMF and EC-MPS overdoses in adults were 
with suicidal intent. This is in accordance with the proportion reported in the medical literature 
to date where 2 of the 3 reports were cases of suicidal intent. Both patients suffered from a 
chronic condition requiring immunosuppression 20, 21. The number of accidental overdoses in 
the home was also higher than for the previously reported CNI and thiopurine overdose 
series: 47% in the current series compared to 11% among CNI overdoses and 30% among 
thiopurine overdoses 17, 18 which further emphasises the need to repeatedly instruct patients 
to keep medicines out of reach of unintended recipients.  
 
4.2 Magnitude and Outcomes 
MMF overdose was associated with symptoms in a dose-dependent manner. These were 
mainly headache or gastrointestinal-related and were minor in nature. Gastrointestinal 
symptoms such as nausea, vomiting, diarrhoea or cramping are also the most common 
adverse effects of these active substances when given in therapeutic doses 1. One case of 
haemodynamically significant hypotension occurred 8 hours after ingestion. This is in 
keeping with the enterohepatic recycling of MPAG, which means a second peak MPA 
concentration is reached approximately 6 – 12 hours after oral ingestion 1. The mechanism 
underlying mycophenolate-induced hypotension is not known.  
Patient 16 was found to be leukopenic 14 hours after overdose 20. Whether this was due to 
the overdose is not certain as the leukocyte count had not been measured during the days 
and weeks immediately preceding the overdose and she was also receiving quetiapine, an 
agent known to be frequently (> 10%) associated with leukopenia 24. In our opinion, the 
mechanism whereby MPA causes leukopenia (disruption of de novo guanosine synthesis) is 
unlikely to lead to such a rapid decline in the leukocyte count and it is likely that the leukocyte 
count was already decreased prior to overdose in this particular case. After overdose in this 
patient, the leukocyte count continued to fall, reaching a nadir 5 days later.  
The oral acute lethal dose 50 (LD50) for MMF in rats is 352 mg/kg, in mice 1000 mg/kg and 
>6000 mg/kg in rabbits, indicating a species-dependence of the lethal dose 25. The maximum 
overdose in this current series was 448 mg/kg. 
 
4.3 Pharmacokinetics: 
The apparent half-life of MPA is 16 – 18 hours; an accurate determination of MPA`s half-life 
is hampered by MPAG`s enterohepatic recirculation 1, 10. In the literature cases studied here, 
terminal half-life was 2.6 h in a case where activated charcoal was given 4 hours after 
overdose (Patient 15), 6.1 h in a case where activated charcoal and cholestyramine were 
given 10 h after overdose (patient 16) and 7.4 h (patient 17). These data imply a reduction in 
the MPA half-life when activated charcoal alone or in combination with cholestyramine is 
used in the management of MMF overdose. A study of liver transplant patients, however, 
also found a shorter terminal disposition half-life (mean 4.54 ± 1.19 h) than the 
pharmacokinetic studies in healthy volunteers 26, 10. Unlike concomitant cyclosporin, 
tacrolimus (the calcineurin inhibitor used in this study) is not known to disrupt the 
enterohepatic cycling of MPAG so this cannot explain the shorter half-life seen 1.  
 4.4 Management 
Due to the rarity of MMF and EC-MPS overdoses, it is not possible to perform randomised 
controlled trials to determine the optimal management, and examination of case data such as 
that presented here is therefore important. 
Patients who ingested 2.5 times or less than their usual or the maximum recommended MMF 
or EC-MPS dose did not develop symptoms and medical treatment or hospitalisation of such 
cases (other than for psychiatric reasons) does not appear to be indicated. Similarly, in our 
opinion, activated charcoal should only be used in cases of definite overdose as its 
administration is not without risk 27. The fact that activated charcoal was only administrated to 
children in the cases reported to STIC most likely reflects their earlier presentation to 
emergency services (all within 1 h – table 3).   
In this case-series, patients who received activated charcoal developed fewer symptoms. 
However, it is not possible to conclude a definite beneficial effect of activated charcoal after 
mycophenolate overdose as these patients had presented earlier and had ingested, on 
average, smaller doses than patients who did not receive activated charcoal.  
The Swiss product information for MMF and EC-MPS do not recommend the use of activated 
charcoal after overdose 1, 2. Other sources, however, recommend that activated charcoal be 
used `early` in overdose of these drugs 14 and that it is most effective when administered 
within 1 h of overdose 13. On the basis of their chemical properties, a good adsorption of 
MMF and EC-MPS onto activated charcoal is to be expected. MMF and EC-MPS have 
molecular weights of 433 and 320 Dalton respectively 28, which means that they are readily 
adsorbed into the 10-20 Å-sized charcoal pores 29. As the absolute bioavailability of MPA 
after oral administration of MMF is high (94%) and MPA reaches its peak plasma 
concentration between 1.5 and 2 hours after ingestion 1, it is reasonable to expect that 
activated charcoal is beneficial when administered within 2 hours after overdose. One can 
also speculate that charcoal administered later than 2 hours would still be of benefit because 
it could reduce the `second peak` resulting from reabsorption of MPAG excreted in the bile, 
thereby minimising the effect of the enterohepatic recirculation. In the cases published by 
Bebarta and Wu, activated charcoal was given 4 and 10 hours after overdose, respectively 21, 
20, and the half-lives were found to be less than expected. This provides some evidence to 
support the use of activated charcoal beyond 2 hours after overdose in MMF and EC-MPS 
overdose.  
The administration of bile acid sequestrants, such as cholestyramine, is recommended in the 
treatment of acute overdose with MMF or EC-MPS in the Swiss product information 1, 2 but 
not specifically by the widely consulted Poisindex® Database 13. By binding parent and 
glucuronidated drug that is excreted in the bile, cholestyramine prevents their reabsorption 
and deglucuronidation, respectively and thereby interrupts the enterohepatic recycling of 
MPAG 10. Patient 16 who ingested 25 g of MMF in suicidal intent, was treated with oral 
cholestyramine (8 g three times daily for three days) commencing 14 h after overdose and 
did not developed hypotension or other symptoms in the time periods when a `second peak` 
might have been expected to occur 20. Also of note in this case was the rapid decrease in 
MPA concentrations after commencement of cholestyramine from 37.2 mg/l at 20 hours to 
1.1 mg/l just 4 hours later.  
Interestingly the STIC case in which hypotension was observed eight hours after overdose 
had neither been treated with activated charcoal nor with cholestyramine. This case also 
illustrates the point that it would seem prudent to monitor patients who have ingested large 
MMF or EC-MPS doses or who are symptomatic at presentation for at least 12 – 24 hours 
after overdose due to the possible risk of delayed hypotension.  
 
4.5 Limitations 
Our study has a number of limitations, primarily related to the small sample size. Larger 
series of MMF or EC-MPS overdoses have, however, not been published. It is likely that our 
data did not capture all cases of overdose which occurred in the referral population. Our data 
are also incomplete, which is the nature of retrospective studies using poison centre data 30. 
Unfortunately, a number of cases were lost to follow-up despite repeated efforts of the STIC 
to contact the treating physicians in the days after presentation. In some cases follow-up took 
place sooner than 7 days after overdose which is the time point when maximum bone 
marrow suppression after ingestion of a bone marrow suppressing agent such as MMF and 
EC-MPS might be expected. A further limitation is the paucity of data regarding blood or 
plasma concentrations which would have allowed stronger conclusions regarding 
pharmacokinetic-pharmacodynamic relationships and the effect of decontamination on drug 
absorption to be drawn. However, such data are extremely difficult to obtain as therapeutic 
drug monitoring for MMF and EC-MPS are not routinely performed.   
5. Conclusion 
 
Acute MMF and EC-MPS overdoses occurred commonly in the context of suicide attempt 
among adults and in the context of accidental poising in the home among children. The acute 
overdoses were well tolerated, with the exception of a 9-fold MMF overdose which was 
associated with hypotension eight hours after ingestion possibly reflecting the enterohepatic 
circulation of MPAG and a case of moderate leukopenia 5 days after a 12.5-fold overdose. 
More data are needed to determine the effect of decontamination with activated charcoal and 
cholestyramine. MMF and EC-MPS overdose patterns, outcomes and management require 
further study and physicians should be encouraged to actively follow-up and report the cases 
in which they are involved. 
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